Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research led by Associate Professor Lisa Heather has found that a drug known as molidustat, currently in clinical trials for another condition, could reduce risk of heart failure after heart attacks.

Human cardiomyocytes in culture showing the myofilaments necessary for contraction of the heart cells (red)

Researchers from the Heather, Carr and Tyler groups have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks. The drug, currently in clinical trials as a potential treatment for a form of anaemia, could help diabetic hearts to recover and reduce their risk of developing heart failure, according to research funded by the British Heart Foundation published in the journal Diabetes.

During a heart attack blood supply to the heart is reduced or cut off, starving the heart of oxygen (hypoxia). In diabetes heart cells are less able to tolerate hypoxia and therefore die more quickly.

Now, DPAG researchers have found that a drug, known as molidustat, can increase levels of a protein that helps cells to adapt and survive after they are starved of oxygen. They hope that giving molidustat to people with diabetes will help their hearts to recover after a heart attack and reduce their risk of further complications, such as heart failure.

Molidustat, which is taken orally, is currently in phase III clinical trials for treating anaemia in chronic kidney disease. It works by increasing levels of a protein called Hypoxia-Inducible Factor 1 (HIF). When oxygen levels fall HIF levels increase, causing it to activate its ‘target’ genes which help cells to adapt and survive. However, previous research has found that people with diabetes have lower levels of HIF in their heart cells.

When the researchers exposed human heart cells with insulin resistance, a characteristic of type 2 diabetes, to low levels of oxygen they found that the increase in HIF protein levels was much lower than in control cells without insulin resistance. But, when they treated the insulin resistant cells with molidustat, the researchers saw increased levels of the HIF protein and activation of its target genes.

Next the team investigated the impact of molidustat on heart function by exposing hearts from rats with and without type 2 diabetes to low levels of oxygen. The function of the diabetic hearts was significantly decreased after the period of low oxygen. However, when these hearts were treated with molidustat their function recovered back to the level of those without diabetes.

HIF is also involved in healing processes that happen after a heart attack, such as the growth of new blood vessels, a process known as angiogenesis. New blood vessels grow to bypass the tissue that has died and ensure a good blood supply to the surrounding areas of the heart that have survived.

Angiogenesis is known to be reduced in diabetic hearts, and this is believed to be a critical step in the development of heart failure. When rats with type 2 diabetes were treated with molidustat the researchers saw increased levels of the signals involved in the growth of new blood vessels. They hope that molidustat treatment could help to improve blood supply to the heart after a heart attack in people with diabetes

Dr Lisa Heather, BHF Intermediate Research Fellow at the University of Oxford, said: 

“Even with optimal management, people with type 2 diabetes still have a higher risk of developing heart and circulatory diseases. They’re then more likely than people without diabetes to develop heart failure after a heart attack.

“Despite this, there are no treatments available to help the diabetic heart recover after a heart attack. We’re hopeful that we’ve identified a drug that can address this unmet need and improve outcomes for people with diabetes after a heart attack.”

Professor Metin Avkiran, Associate Medical Director at the British Heart Foundation, said:

“Heart and circulatory diseases are the leading cause of death in people with diabetes, a condition which affects nearly 5 million people in the UK.

“These promising results suggest that drugs which stabilise HIF could become a new treatment to reduce the risk of heart failure after a heart attack in people with diabetes. Further research is now needed to translate these early stage findings into clinical benefit.”

 

The full paper, "Activation of HIF1α Rescues the Hypoxic Response and Reverses Metabolic Dysfunction in the Diabetic Heart" is available to read in the journal Diabetes.

The paper is authored by Maria da Luz Sousa Fialho, Ujang Purnama, Kaitlyn Dennis, Claudia Montes Aparicio, Marcos Castro Guarda, Emmanuelle Massourides, Damian Tyler, Carolyn Carr and lead researcher Lisa Heather.

This research was also funded by the Rosetrees Trust.

Story by the British Heart Foundation.

Similar stories

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between core investigators Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institutet, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.

DPAG Researchers honoured for their work in cardiac metabolism

Kaitlyn Dennis, Ujang Purnama and Kerstin Timm have won prizes across each of the three award categories at this year’s Society for Heart and Vascular Metabolism conference, demonstrating DPAG's continued excellence in cardiac metabolism research.

Richard Tyser and Jack Miller honoured by the British Society of Cardiovascular Research

Dr Richard Tyser is this year’s winner of the Bernard and Joan Marshall Early Career Investigator Prize, and Dr Jack Miller has received a runner-up award, at the British Society of Cardiovascular Research Autumn Meeting.

Blood bank storage can reduce ability of transfusions to treat anaemia

New research from the Swietach Group in collaboration with NHS Blood and Transplant has demonstrated that the process of storing blood in blood banks can negatively impact the function of red blood cells and consequently may reduce the effectiveness of blood transfusions, a treatment commonly used to combat anaemia.